获得性血友病A的治疗进展

林欢; 黎承平; 吴炳芬; 冉立

获得性血友病A的治疗进展

昆明医科大学第一附属医院

基金项目:

基金：国家自然科学基金资助项目 (2015FB049); 云南省医疗卫生单位内设研究机构科研基金资助项目 (2017NS047);

计量
- 文章访问数: 1731
- HTML全文浏览量: 571
- PDF下载量: 232
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-13

Progress in the Treatment of Acquired Hemophilia A

Funds:

基金：国家自然科学基金资助项目 (2015FB049); 云南省医疗卫生单位内设研究机构科研基金资助项目 (2017NS047);

摘要

摘要: 获得性血友病A是一种由于多种原因导致机体产生凝血因子Ⅷ抗体引起的凝血缺陷性疾病, 该病发病率极低, 且病死率较高, 因该病少见, 故常误诊, 以致延误治疗, 故早期诊断及及时治疗对减少该病的死亡率至关重要.对于该病的治疗原则主要为控制急性出血、根除抑制物、治疗原发病, 故合理及个性化选择治疗方案也很关键.
- 获得性血友病A /
- 凝血因子Ⅷ /
- 治疗
Abstract: Acquired hemophilia A is a deficiency disease caused by blood coagulation factor VIII antibodies due to a variety of causes, The disease incidence rate is extremely low, but the mortality rate is high. This disease is often misdiagnosed, resulting in delays in treatment, so early diagnosis and timely treatment is crucial for reducing the mortality. The principle of treatment for the disease is mainly to control acute bleeding, eradicate inhibitor, and treat the primary disease, therefore, rational and personalized choices of treatment are also critical.
- Acquired hemophilia A /
- Coagulation factor /
- Treatment

HTML全文

参考文献(16)

[1]	[1]COLLINS P W.Treatment of acquired hemophilia A[J].J Thromb Haemost, 2007, 5 (5) :893-900.
[2]	[2]P W C, CHALMERS E, HART D, et al.Diagnosis and management of acquired coagulation inhibitors:a guideline from UKHCDO[J].British Journal of Haematology, 2013, 162 (6) :758-773.
[3]	[3]BAUDO F, COLLINS P, HUTHK?HNE A, et al.Management of bleeding in acquired hemophilia A:results from the European Acquired Haemophilia (EACH2) Registry[J].Bjog An International Journal of Obstetrics&Gynaecology, 2012, 119 (12) :1529-1537.
[4]	[4]KRUSEJARRES R, KEMPTON C L, BAUDO F, et al.Acquired hemophilia A:Updated review of evidence and treatment guidance[J].American Journal of Hematology, 2017, 92 (7) :695-705.
[5]周荣富, 王鸿利.获得性血友病的临床研究[J].国际输血及血液学杂志, 2004, 27 (1) :36-40.
[6]	[6]LILLICRAP D, SCHIVIZ A, APOSTOL C, et al.Porcine recombinant factor VIII (Obizur;OBI-1;BAX801) :product characteristics and preclinical profile[J].Haemophilia, 2016, 22 (2) :308-317.
[7]	[7]MA A D, KESSLER C M, AL-MONDHIRY H A, et al.Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia:final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study[J].Blood Coagulation&Fibrinolysis An International Journal in Haemostasis&Thrombosis, 2016, 28 (2) :87-116.
[8]	[8]SHANG-YI H, WOEI T, SHYUANN-YUH L, et al.A study of 65 patients with acquired hemophilia A in Taiwan[J].Journal of the Formosan Medical Association, 2015, 114 (4) :321-327.
[9]	[9]FRANCHINI M.Postpartum acquired factor VIII inhibitors[J].American Journal of Hematology, 2006, 81 (10) :768-773.
[10]	[10]COLLINS P, BAUDO F, KNOEBL P, et al.Immunosuppression for acquired hemophilia A:results from the European Acquired Haemophilia Registry (EACH2) [J].Blood, 2012, 120 (1) :47-55.
[11]	[11]VAUTIER M, DE B H, CREVEUIL C, et al.Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia:A retrospective single-center study[J].Medicine, 2016, 95 (48) :e5232.
[12]魏卿, 牛挺.获得性血友病A免疫抑制剂的治疗进展[J].华西医学, 2014, 29 (4) :646-650.
[13]	[13]D’ARENA G, GRANDONE E, MINNO M N D D, et al.Acquired hemophilia a successfully treated with rituximab[J].Mediterranean Journal of Hematology&Infectious Diseases, 2015, 7 (1) :e2015024.
[14]	[14]PESCOVITZ M D.RITUXIMAB, an anti-cd20 monoclonal antibody:history and mechanism of action[J].American Journal of Transplantation Official Journal of the American Society of Transplantation&the American Society of Transplant Surgeons, 2006, 6 (5 Pt 1) :859-866.
[15]	[15]DYKES A C, WALKER I D, LOWE G D O, et al.Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors:a 2-year review.[J].Haemophilia the Official Journal of the World Federation of Hemophilia, 2001, 7 (2) :160-163.
[16]	[16]ZEITLER H, ULRICH-MERZENICH G, HESS L, et al.Treatment of acquired hemopfdlia by the Bonn-Malmo Protocol:Documentation of an in vivo immunomodulating concept[J].Blood, 2005, 105 (6) :2287-2293.

相关文章(20)

[1]	金以超, 王晓川, 敖春萍, 徐良恒. 瘢痕疙瘩相关性瘙痒的发病机制及治疗研究进展, 昆明医科大学学报.
[2]	黄宝川, 李武全, 唐毅. 云南烧伤中心1500例小儿烧伤患者流行病学分析, 昆明医科大学学报.
[3]	陈敏. 大剂量盐酸氨溴索在慢性阻塞性肺疾病急性加重患者治疗中的临床价值, 昆明医科大学学报.
[4]	谢作舟. 老年糖尿病、高血压患者持续呼吸困难的治疗, 昆明医科大学学报.
[5]	舒敬奎. 内科胸腔镜在结核性包裹性胸腔积液诊治中的应用, 昆明医科大学学报.
[6]	王浩. 序贯治疗对获得性维生素K依赖性凝血因子缺乏症的临床疗效分析, 昆明医科大学学报.
[7]	林少芳. 90例老年慢性阻塞性肺疾病合并自发性气胸治疗体会, 昆明医科大学学报.
[8]	耿鑫. 脑深部电刺激治疗帕金森病1例报道, 昆明医科大学学报.
[9]	刘玲. 苯巴比妥钠联合蓝光照射治疗难治性或迁延性新生儿黄疸的研究, 昆明医科大学学报.
[10]	张蕾. 微创穿刺治疗高血压性脑出血112例临床分析, 昆明医科大学学报.
[11]	代冬梅. 沙利度胺治疗皮肤转移性Crohn病1例报道, 昆明医科大学学报.
[12]	方克伟. 腺性输尿管炎5例临床诊断与治疗, 昆明医科大学学报.
[13]	申思敏. Castleman病文献复习附1例报道, 昆明医科大学学报.
[14]	黄宁玉. 临床路径管理模式应用于急性ST段抬高性心肌梗死治疗的重要性, 昆明医科大学学报.
[15]	路萍. 部分脾栓塞治疗难治性特发性血小板减少性紫癜16例临床观察, 昆明医科大学学报.
[16]	詹辉. 不同型号经皮肾通道治疗复杂性上尿路结石效果观察, 昆明医科大学学报.
[17]	李显丽. 艾塞那肽治疗肥胖2型糖尿病的临床疗效观察, 昆明医科大学学报.
[18]	杨义明. 结直肠癌性梗阻48例临床诊治体会, 昆明医科大学学报.
[19]	唐继红. 肝脏局灶性结节性增生12例临床分析, 昆明医科大学学报.
[20]	陈祖聪. 部分性脾动脉栓塞术治疗继发性脾功亢进25例临床观察, 昆明医科大学学报.